tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss
PremiumCompany AnnouncementsBright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss
21d ago
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline
Premium
Company Announcements
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline
2M ago
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline
Premium
Company Announcements
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline
2M ago
Bright Minds price target raised to $142 from $82 at Baird
PremiumThe FlyBright Minds price target raised to $142 from $82 at Baird
2M ago
Bright Minds price target raised to $147 from $72 at BTIG
Premium
The Fly
Bright Minds price target raised to $147 from $72 at BTIG
2M ago
Bright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug Pipeline
Premium
Company Announcements
Bright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug Pipeline
2M ago
Bright Minds announces results from Phase 2 BREAKTHROUGH trial of BMB-101
PremiumThe FlyBright Minds announces results from Phase 2 BREAKTHROUGH trial of BMB-101
2M ago
Bright Minds Biosciences Sets January 6 Webcast for BMB-101 Phase 2 Topline Results in Drug-Resistant Absence Seizures
Premium
Company Announcements
Bright Minds Biosciences Sets January 6 Webcast for BMB-101 Phase 2 Topline Results in Drug-Resistant Absence Seizures
2M ago
Bright Minds Biosciences: Buy Rating Reiterated on BMB-101’s Potential Best-in-Class Profile and Multi-Billion-Dollar Peak Sales Opportunity
Premium
Ratings
Bright Minds Biosciences: Buy Rating Reiterated on BMB-101’s Potential Best-in-Class Profile and Multi-Billion-Dollar Peak Sales Opportunity
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100